Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28125877 | 0.80 | POLB (0.41) | POLBAPEX1TDP1L3MBTL1HDAC4 | |
| SCHEMBL17900455 | 0.77 | PPME1 (0.49) | POLBAPEX1TDP1L3MBTL1 | |
| SCHEMBL30599059 | 0.73 | TSHR (0.44) | POLBAPEX1TDP1L3MBTL1 | |
| SCHEMBL30599061 | 0.73 | TSHR (0.44) | POLBAPEX1TDP1L3MBTL1 | |
| SCHEMBL27851095 | 0.72 | POLB (0.35) | POLBAPEX1TDP1L3MBTL1HDAC4 | |
| SCHEMBL16540512 | 0.72 | RAPGEF4 (0.56) | POLBL3MBTL1 | |
| SCHEMBL8189051 | 0.71 | ACLY (0.46) | POLB | |
| SCHEMBL782203 | 0.70 | — | — | |
| SCHEMBL8935030 | 0.69 | ACLY (0.39) | L3MBTL1 | |
| SCHEMBL14399002 | 0.69 | FABP4 (0.36) | POLBAPEX1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544359-B2 | 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors | Infex Therapeutics Limited (GB) | 2026-02-10 | — | — | US | disclosed |
| CN-119100967-A | 1-Aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors | 英菲克斯治疗有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-119100967-A | 1-Aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors | 英菲克斯治疗有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-119100967-A | 1-Aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors | 英菲克斯治疗有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-114728902-B | 1-Aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors | 英菲克斯治疗有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-114728902-B | 1-Aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors | 英菲克斯治疗有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-116209652-A | Synthesis of pyrrole acid derivatives | 英菲克斯治疗有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20230018460-A1 | 1-AMINOSULFONYL-2-CARBOXYPYRROLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Infex Therapeutics Limited (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-4061800-A1 | 1-AMINOSULFONYL-2-CARBOXYPYRROLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Infex Therapeutics Limited (GB) | 2022-09-28 | — | — | EP | disclosed |
| EP-4061800-A1 | 1-AMINOSULFONYL-2-CARBOXYPYRROLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Infex Therapeutics Limited (GB) | 2022-09-28 | — | — | EP | disclosed |
| CN-114728902-A | 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors | 英菲克斯治疗有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728902-A | 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors | 英菲克斯治疗有限公司 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544359-B2 | 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors | CBR1, CBR3, SRR | POLB 1356/4885APEX1 662/4885TDP1 4365/4885 |
| US-20230018460-A1 | 1-AMINOSULFONYL-2-CARBOXYPYRROLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | CPN1, CMBL, ALDH7A1 | POLB 1373/4885APEX1 408/4885TDP1 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.